Can a single drug keep rare blood vessel disease at bay?
NCT ID NCT00748644
First seen Nov 20, 2025 · Last updated May 14, 2026 · Updated 19 times
Summary
This study looked at whether rituximab can help people with a rare autoimmune disease called ANCA-associated vasculitis stay in remission longer than the standard treatment, azathioprine. 117 adults who were already in remission took either rituximab or azathioprine for 18 months, plus 10 months of follow-up. The main goal was to see which group had fewer major relapses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.